Home > Healthcare & Medical Devices > Monoclonal Antibodies Market

Monoclonal Antibodies Market Size By Type (Fully Human, Humanized, Chimeric), By Application (Oncology, Autoimmune Diseases, Infectious Diseases), By End-use (Hospitals, Clinics), COVID19 Impact Analysis, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2021 - 2027

  • Report ID: GMI5065
  • Base Year: 2020
  • Report Format: PDF

Industry trends

Monoclonal Antibodies Market size was valued at USD 150 billion in 2020 and is projected to grow at a CAGR of 13.8% from 2021 to 2027.

Monoclonal Antibodies Market Overview

Get more details on this report - Request Free Sample PDF

Monoclonal antibodies (mAb or moAb) are referred to as identical immunoglobulins developed from single B-cell with specific target antigens. Advancements in mAb development technologies have improved its potential in basic research and clinical applications. Currently, number of monoclonal antibodies have been approved by the U.S. FDA and the European Commission with therapeutic applications in cancer, autoimmune diseases, blood disorders, cardiovascular diseases and infectious diseases among others. With numerous applications and effectiveness in disease treatment, the market will witness lucrative growth during the forecast timeframe.  

The prevalence of chronic and rare diseases is crucial revenue growth driver in the monoclonal antibodies market. For instance, patient diagnosed with cancer require long-term medication with frequent administration of moAb as prescribed during the course of treatment. Along with disease prevalence, continuous development efforts by industry players to launch new products will strengthen the market growth. Also, several leading manufacturers are focused on R&D to provide existing therapies for extended disease applications. This has assisted companies in stimulating revenue generation associated with mAb products, thereby contributing to the overall market expansion.

Efficiency in treatment of emerging infectious diseases including COVID-19 will foster the market revenue

Monoclonal antibodies market has experienced significant positive impact of COVID-19 as several mAbs have potential in treatment of coronavirus infection. The companies are conducting clinical trials to further boost the development of highly potential therapies. Recently, the U.S. FDA has issued emergency use authorization (EUA) for combined administration of Casirivimab and Imdevimab in patients with mild to moderate infection. Moreover, Roche received EUA for this monoclonal antibody cocktail by the Central Drugs Standards Control Organisation in India. With potential in minimizing infection severity in treatment of COVID-19, the industry will continue to observe revenue growth during pandemic.

To eliminate disruptions in development and distribution activities, firms have entered into collaborative agreements. For instance, AbbVie entered in partnership with Harbour BioMed (HBM), Utrecht University (UU) and Erasmus Medical Center (EMC), with an aim to develop moAb for treatment of COVID-19. This will advance fully human antibody acting against virus through conserved domain of its spike protein. Thus, launch and acceptance of such therapies will lucratively drive the monoclonal antibodies market demand.

Specificity of monoclonal antibody therapeutics with human genomes will influence product adoption in disease treatment

Monoclonal Antibodies Market Demand

Get more details on this report - Request Free Sample PDF

Human-derived antibody genes increase its specificity to human genomes. The companies providing fully human antibody therapeutics have showcased noteworthy revenue growth in past few years. For instance, Humira has witnessed strong revenue since its launch and has become one of the leading drugs in the market. Additionally, efforts by industry leaders in development of human monoclonal antibody therapy for COVID-19 treatment will offer growth opportunities to the segment during the forecast period.

High patient outcomes with targeted therapies will strengthen the monoclonal antibodies market value

Oncology segment accounted for 40% of the revenue share in 2020. Monoclonal antibodies are highly specific and have the ability to target similar epitopes that increase their efficiency in treatment. Thus, mAbs are majorly used in targeted therapies for cancer. Most of the mAb have multiple applications that offers advantage of single mAb to target various types of cancer.

Increasing prevalence of cancer across the globe has driven the demand for specialized treatments. According to the World Health Organization, cancer is amongst the leading causes of death responsible for nearly 10 million deaths in 2020. Thus, to cater to increasing demand, the companies are undertaking developmental activities that have resulted in extensive product pipeline for cancer monoclonal antibodies. Therefore, increasing number of product introductions in future will offer unprecedented growth opportunities to the segment.

Increasing patient inflow accessing disease treatment in hospitals will simulate the monoclonal antibodies market progression

As most of the monoclonal antibodies are recommended to use by healthcare professionals, hospitals have registered acceptance in recent years. Hospitals offer various specialty treatments for cancer as well as infectious diseases that will augment the segment growth in future. Usage of advanced technologies and expertise in specialty treatments will continue to increase patient preference for hospitals. Furthermore, favourable reimbursement policies in government hospitals in some countries increases treatment affordability to patients that will strengthen growth potential of monoclonal antibodies in hospitals.

Presence of leading industry stakeholders catering to attractive product demand will continue to strengthen the market growth in North America

North America monoclonal antibodies market captured over 47% of revenue share in 2020 led by presence of leading industry participants with strong product demand in the market. Expansion of manufacturing capacities will further boost product availability and sales. Moreover, increasing number of product approvals in the U.S. and Canada will stimulate the regional growth during the forecast timeframe.

Product launch and collaborations to broaden accessibility aid the companies in business expansion

The global monoclonal antibodies market is dominated by players including AbbVie Inc., F. Hoffmann-La Roche, Bristol Myers Squibb, Amgen and Novartis AG among others. These competitors are adopting various business growth strategies to strengthen their market footprint.

Some of the recent industry developments:

  • In September 2020, Eli Lilly and Company collaborated with Amgen to expand antibody manufacturing and supply capacity of COVID-19 therapies. This has helped the company in continuing market distribution of its products amid pandemic.  
  • In July 2020, UCB announced collaboration agreement with Roche for development of antibody treatment used in Alzheimer's disease. This has enhanced product development capabilities of the company with Roche’s global presence in the field.  

The monoclonal antibodies market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2016 to 2027 for the following segments:

Market, By Type

  • Fully human
  • Humanized
  • Chimeric
  • Others

Market, By Application

  • Oncology
  • Autoimmune diseases
  • Infectious diseases
  • Others

Market, By End-use

  • Hospitals
  • Clinics
  • Others

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
Authors: Sumant Ugalmugle, Rupali Swain

Frequently Asked Questions (FAQ) :

Monoclonal antibodies market size reached USD 150 billion in 2020 and is expected to grow at a 13.8% CAGR up to 2027.

Humanized monoclonal antibody industry is expanding due to ongoing developments in human monoclonal antibody therapy for COVID-19 treatment.

Oncology application segment accounted for more than 40% of monoclonal antibodies industry share and will expand as mAb can target various types of cancer.

The market for monoclonal antibodies in North America captured over 47% revenue share in 2020 and will expand led by a strong product demand and the presence of major industry players.

The COVID-19 pandemic has had a positive impact on the industry due to the potential of moAb in COVID-19 treatment.

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Published Date: Jun 2021
  • Companies covered: 12
  • Tables & Figures: 184
  • Countries covered: 16
  • Pages: 150

Get a report that explains COVID-19 impact on this market

 Request Free Sample

Budget constraints? Get in touch with us for special pricing

Request Discount